The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non–small cell lung cancer (NSCLC).
C. Sorlini
No relevant relationships to disclose
S. Barni
No relevant relationships to disclose
F. Petrelli
No relevant relationships to disclose
S. Novello
No relevant relationships to disclose
F. De Marinis
No relevant relationships to disclose
T. M. De Pas
No relevant relationships to disclose
F. Grossi
No relevant relationships to disclose
A. Bearz
No relevant relationships to disclose
M. Mencoboni
No relevant relationships to disclose
M. Aieta
No relevant relationships to disclose
A. Caprioli
No relevant relationships to disclose
P. Antonelli
No relevant relationships to disclose
N. Zilembo
No relevant relationships to disclose
A. Bachi
No relevant relationships to disclose
I. Floriani
No relevant relationships to disclose
H. Roder
Employment or Leadership Position - Biodesix
Stock Ownership - Biodesix
J. Roder
Employment or Leadership Position - Biodesix
Stock Ownership - Biodesix
J. Grigorieva
Employment or Leadership Position - Biodesix
Stock Ownership - Biodesix
C. Lazzari
No relevant relationships to disclose
V. Gregorc
No relevant relationships to disclose